Celldex Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Celldex Therapeutics sits in the top decile of US sponsors by registered trial count (#420 of 15,742 sponsors by registered trial count).
Celldex Therapeutics: 42 sponsored US clinical trials, 3 recruiting.
Celldex Therapeutics sponsors 42 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 25 completed. 5 of these trials are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Spontaneous Urticaria, with 3 trials.
Top-decile sponsor footprint
Celldex Therapeutics ranks in the top decile of sponsors by registered trial count (#420 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
25 of 34 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (73.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
42 total, page 1 of 1
A Study of CDX-622 in Participants With Mild to Moderate Asthma
NCT07330778
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT07266402
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392
A Study of Barzolvolimab in Patients With Atopic Dermatitis
NCT06727552
A Phase I Study of CDX-622
NCT06650761
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023
A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT06366750
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
NCT05774184
A Study of CDX-585 in Patients With Advanced Malignancies
NCT05788484
A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
NCT05405660
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT05368285
A Study of CDX-0159 in Patients With Prurigo Nodularis
NCT04944862
A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects
NCT05031624
A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT04538794
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
NCT04440943
A Phase 1 Study of CDX-0159
NCT04146129
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
NCT03254927
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
NCT03329950
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
NCT02837991
A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
NCT02642016
A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
NCT02473731
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
NCT02543645
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
NCT02456701
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
NCT02386111
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
NCT02413827
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
NCT02335918
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
NCT02302339
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
NCT02200380
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
NCT02014909
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
NCT01997333
Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
NCT01791686
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
NCT01498328
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
NCT01480479
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
NCT01460134
A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers
NCT01465139
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
NCT01156753
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
NCT01094496
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
NCT00948961
Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
NCT00458601
Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
NCT00648102
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
NCT00709462
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 13 |
| Phase 3 | 5 |
Therapeutic Areas
What is open in the Celldex Therapeutics pipeline
3 recruiting of 42 indexed (7% open); 25 completed (60%).
Phase mix: 5 late (III/IV) vs 37 early (I/II) (early-phase heavy).
Top condition: Chronic Spontaneous Urticaria (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Celldex Therapeutics: open-pipeline peers nationwide
Peers matched on 42 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Celldex Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 42 trials (± recruiting share)
- Academic and Community Cancer Research United · 42 trials · 14% recruiting
- Ascensia Diabetes Care · 42 trials · 0% recruiting
- Avid Radiopharmaceuticals · 42 trials · 0% recruiting
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 42 trials · 0% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Carol Fabian, MD · 7% recruiting · 14 trials
- Kaiser Permanente · 7% recruiting · 294 trials
- Mannkind Corporation · 7% recruiting · 42 trials
- Minneapolis Veterans Affairs Medical Center · 7% recruiting · 28 trials
Related
What to do with this Celldex Therapeutics page
42 registered trials is a research-attention snapshot, not an endorsement of Celldex Therapeutics or any single study.
- 3 of Celldex Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Chronic Spontaneous Urticaria is the condition Celldex Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Spontaneous Urticaria trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Celldex Therapeutics pipeline card: 42 registered trials from official public datasets.Report a data error.